Conatus' $21.8mm FOPO to fund emricasan trials
Conatus Pharmaceuticals Inc. (hepatic diseases) netted $21.8mm in a follow-on public offering of 4mm shares (including the overallotment) at $5.75. It will use the money to continue developing and prep for registration trials of its Phase II pan-caspase protease inhibitor emricasan in post-liver transplant HCV clearance and liver cirrhosis (including with portal hypertension).
- Specialty Pharmaceuticals
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.